Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.80.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday, November 11th.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock opened at $1.14 on Thursday. The stock’s fifty day moving average price is $1.41 and its two-hundred day moving average price is $1.51. Regulus Therapeutics has a one year low of $0.83 and a one year high of $3.79.

Insider Buying and Selling at Regulus Therapeutics

In other news, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the transaction, the vice president now owns 54,634 shares of the company’s stock, valued at approximately $68,838.84. This represents a 41.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph P. Hagan sold 115,290 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $145,265.40. Following the sale, the chief executive officer now directly owns 222,572 shares in the company, valued at $280,440.72. This trade represents a 34.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 223,998 shares of company stock valued at $282,237. 4.35% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Creative Planning acquired a new stake in shares of Regulus Therapeutics during the 3rd quarter valued at $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter valued at about $33,000. Jane Street Group LLC acquired a new stake in shares of Regulus Therapeutics during the third quarter valued at about $46,000. State Street Corp grew its holdings in shares of Regulus Therapeutics by 3.5% during the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock worth $1,572,000 after purchasing an additional 33,496 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after buying an additional 37,480 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.